Latest News:28/June/2013:MESH Sceintefic program started today..»28/June/2013:بدء نشاط مدرسة الشرق الأوسط لأمراض الكبد..»13/May/2013:adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma..»13/May/2013:Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening..»13/May/2013:FDA Limits Duration, Usage of Tolvaptan Due to Possible Liver Injury..»13/May/2013:Nephrology Online Course (NOC) on CKD..»4/May/2013:FDA OKs Kcentra for Fast Fix of Coumadin Bleeds..»22/April/2013:فى ذمه الله..وفاه حرم أ.د. عمرو حلمى..»17/April/2013:سيد الرئيس " محمد مرسي  يكرم أ/د جمال الدين عصمت في عيد العلم بمناسبة حصول سيادته على جائزة الدولة التقديرية في العلوم الطبية لعام..»27/December/2011:إختيار الأستاذ الدكتور/ جمال عصمت نائبا لرئيس جامعة القاهرة للدراسات العليا..»16/November/2011:Dr.Zayady had passed away..»16/November/2011:البقاء لله :توفى اليوم الى رحمة الله د. عبد الرحمن الزيادى أستاذ الكبد والجهازهضمى..»13/October/2011:دعوة للإنضمام إلى الطريق الأخر...القوة الثالثة..»26/August/2011:توفى الى رحمة الله تعالى بألمانيا المغفور له بإذن الله - الاستاذ الدكتور/ مصطفى كمال..»29/May/2011:New Treatments for Hepatitis C..»23/March/2010:Nitazoxanide is now available in Egypt..»23/March/2010:When and how to evaluate mildly elevated liver enzymes in apparently healthy patients..»28/February/2010:نقابة الأطباء تفتح باب التبرعات لتقديم الزكاة لأعضائها..»15/January/2010:New Project By NMMA supported by Coca Cola International..»

Member's Login

login:
Password:
Skip Navigation Links.

Egyptian Liver Journal>>April issue

Books Library:

Migrating Birds:



Suggestion Home

Latest News


?Here you can read about the latest news from the network that we found usful for every client intersted in our site's topics,here u will find a variety of news that we hope it afficts your life positively..!!


FDA Limits Duration, Usage of Tolvaptan Due to Possible Liver Injury- 5/13/2013 12:00:00 AM

The US Food and Drug Administration (FDA) has determined that tolvaptan (Samsca) should not be used for longer than 30 days and should not be used in patients with underlying liver disease because it can cause liver injury, potentially requiring liver transplant, or death.

Search News


Date From:
To:
 



Upcoming Events

International Events:


National Events:

Pioneers: